Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › ACRS
SUPERSTRING CAPITAL MANAGEMENT LP position in ACRS
ACLARIS THERAPEUTICS INC · Health Care
SUPERSTRING CAPITAL MANAGEMENT LP reported holding 257,675 shares of ACRS (ACLARIS THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.4M, representing 0.86% of its reported portfolio and ranking #23 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed ACRS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SUPERSTRING CAPITAL MANAGEMENT LP's ACRS position evolved
SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in ACRS in Q1 2026 at 366,490 shares (US$1.4M). Across 2 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 257,675 shares valued at US$1.4M — a reduction of -108,815 shares quarter over quarter.. Notable position changes include a 30% trim in Q2 2026 (shares were roughly flat over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 366.49K | $1.37M | New |
| Q2 2026 | 257.68K | $1.36M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACRS and 13F data
ACRS (ACLARIS THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ACRS — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$67.3M), BML Capital Management, LLC (US$63.3M), Deep Track Capital, LP (US$49.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACRS
- RA CAPITAL MANAGEMENT, L.P. 12.72M sh · $67.30M · Q2 2026
- BML Capital Management, LLC 11.97M sh · $63.35M · Q2 2026
- Deep Track Capital, LP 9.35M sh · $49.44M · Q2 2026
- Vivo Capital, LLC 6.69M sh · $35.41M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.93M sh · $26.06M · Q2 2026
- Rock Springs Capital Management LP 4.33M sh · $22.91M · Q2 2026
- Decheng Capital LLC 4.04M sh · $21.38M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.95M sh · $10.30M · Q2 2026
- Kalehua Capital Management LLC 1.83M sh · $9.69M · Q2 2026
- Jones Hill Capital LP 1.76M sh · $9.31M · Q2 2026
- Palo Alto Investors LP 1.61M sh · $8.54M · Q2 2026
- MPM BioImpact LLC 1.04M sh · $5.51M · Q2 2026
More on SUPERSTRING CAPITAL MANAGEMENT LP
FAQ
How long has SUPERSTRING CAPITAL MANAGEMENT LP held ACRS?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed ACRS holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in ACRS?
As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 257.68K shares of ACRS (ACLARIS THERAPEUTICS INC), valued at $1.36M, representing 0.86% of its reported portfolio and ranking #23.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling ACRS?
In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP reduced its position in ACRS.
Which other funds hold ACRS?
Other major institutional holders of ACRS include RA CAPITAL MANAGEMENT, L.P., BML Capital Management, LLC, Deep Track Capital, LP, among 44 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.